THE USE OF POSITRON EMISSION TOMOGRAPHY IN IDENTIFYING AND QUANTIFYING RECEPTORS INVOLVED IN SCHIZOPHRENIA.
- BROOKHAVEN NATIONAL LABORATORY
Schizophrenia is a devasting mental disorder that is the focus of a great deal of research. Some symptoms of the disease, such as auditory hallucinations and delusions, can be ameliorated with drug treatment, whereas other symptoms, such as social withdrawal and cognitive decline, remain uncontrolled. It is possible that these latter symptoms that are often termed ''negative symptoms'' are the result of anatomical and neurochemical abnormalities, whereas those symptoms of the disease such as auditory hallucinations that are termed ''positive symptoms'' may be a result of only neurochemical disorders. The drugs used to treat schizophrenia are designated neuroleptics. The term neuroleptic was chosen to emphasize the similarity of pharmacological profiles of drugs with entirely different chemical structures. Especially prominent features of the effects of neuroleptics include the following: a state of affective indifference; a decrease in locomotor activity; a decrease in excitation, agitation, and aggressiveness; and an antipsychotic action in patients with acute as well as chronic psychoses.
- Research Organization:
- Brookhaven National Lab., Upton, NY (US)
- Sponsoring Organization:
- USDOE Office of Energy Research (ER) (US)
- DOE Contract Number:
- AC02-98CH10886
- OSTI ID:
- 798546
- Report Number(s):
- BNL--69212; KP140102
- Country of Publication:
- United States
- Language:
- English
Similar Records
Left globus pallidus abnormality in never-medicated patients with schizophrenia
In vivo assessment of dopamine and serotonin receptors measured by C-11 n-methylspiperone (NMSP) in patients with schizophrenia